HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kropp, J. Articles by Biersack, H.-J. Search for Related Content PubMed PubMed Citation Articles by Kropp, J. Articles by Biersack, H.-J.

Inhalation of [¹²³I]₁-Protease Inhibitor: Toward a New Therapeutic Concept of ₁-Protease Inhibitor Deficiency?

Department of Nuclear Medicine, University Hospital of Technische Universität Dresden, Dresden; Department of Pneumology, University Hospital Essen, Ruhrlandklinik, Essen; Nuclear Medicine, Mainz-Kastel, Mainz; Bayer Vital, Leverkusen; Pharma Research Center, Bayer AG, Wuppertal; and Department of Nuclear Medicine, University Hospital of Bonn, Bonn, Germany

The ₁-protease inhibitor (₁-Pi) is separated from human serum and is therefore extremely expensive. Because only 2%–3% concentrates in the lung after intravenous administration, inhalational therapy for ₁-Pi deficiency would seem likely to be better. The aims of this study were therefore to determine the pattern of deposition of inhaled ₁-Pi labeled with ¹²³I and measure the amount deposited in the lungs. Methods: Eighteen patients with congenital severe ₁-Pi deficiency were enrolled in the study. The low-specific-activity ¹²³I-labeled ₁-Pi aerosol (median particle size ± SD, 3.9 ± 2.5 µm) was generated by an air pressure–driven nebulizer. The patients inhaled for an average of 23.6 ± 8.9 min. Static scintigrams in two projections were acquired immediately after (T₁) and 1 (T₂), 4 (T₃), and 24 h (T₄) after inhalation. The patients were divided into the following three groups according to their forced expiratory volume in 1 s (FEV₁): group I, 40% of predicted normal (n = 8); group II, 40% < FEV₁ 60% of predicted normal (n = 4); group III, >60% of predicted normal (n = 6). Results: The absolute percentage uptake values of ₁-Pi in group I were 12.4 for T₁, 7.3 for T₂, 4.6 for T₃, and 1.2 for T₄; in group II the values were 13.0, 9.6, 6.2, and 2.0, respectively; and in group III, 14.6, 11.4, 6.5, and 3.6, respectively. Differences between the groups were generally statistically significant. Between T₁ and T₂, the probability value was <0.05 for group I versus group II, <0.006 for group I versus group III, and <0.39 for group II versus group III. Between T₁ and T₃, the probability value was <0.29 for group I versus group II, <0.22 for group I versus group III, and <0.94 for group II versus group III. Retention (between T₁ and T₄) was also dependent on the grade of the disease: P < 0.2 for group I versus group II, P < 0.001 for group I versus group III, and P < 0.02 for group II versus group III. Grading of the uptake pattern by three independent experienced investigators (87% agreement) revealed a peripheral deposition that was group dependent. We found that greater peripheral deposition corresponded with lower lung functional impairment: P < 0.5 for group I versus group II, P < 0.01 for group I versus group III, and P < 0.08 for group II versus group III. Degradation also corresponded with functional impairment: P < 0.05 for group I versus group II, P < 0.006 for group I versus group III, and P < 0.3 for group II versus group III. Conclusion: The results of this study show that sufficient amounts of ₁-Pi can be deposited in the periphery of the lung by inhalation at least in patients with low-grade disease. Inhalation of ₁-Pi may thus represent a new and more convenient route of drug administration.

Key Words: ₁-protease inhibitor • antitrypsin • Prolastin • inhalation therapy • ¹²³I-₁-Pi

This article has been cited by other articles:

				M. P. Limberis and J. M. Wilson Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered PNAS, August 29, 2006; 103(35): 12993 - 12998. [Abstract] [Full Text] [PDF]